Trial Outcomes & Findings for Effect of Local Anesthetic Dose on Interscalene Block (NCT NCT01701115)

NCT ID: NCT01701115

Last Updated: 2017-10-04

Results Overview

The primary outcome will be handgrip strength as measured by a dynamometer. A reading will be obtained at baseline (before the interscalene block) and 60 minutes post-operative.

Recruitment status

COMPLETED

Study phase

NA

Target enrollment

154 participants

Primary outcome timeframe

Difference between between baseline and postoperative.

Results posted on

2017-10-04

Participant Flow

Participant milestones

Participant milestones
Measure
Low Dose (20 mL) Local Anesthetic
Intervention to be administered is a total volume of 20 mL local anesthetic containing a 1:1 mixture of 1.5% Mepivacaine: 0.5% Bupivacaine. Low Dose (20 ml) Local Anesthetic Volume for Interscalene Block: Anesthetic volume: Investigational group: A 1:1 Mepivacaine 1.5%: Bupivacaine 0.5% mixture for a total of 20 mL Low Dose (20 mL) Local Anesthetic (Mepivacaine:Bupivacaine)
Control Dose (40 mL) Local Anesthetic
Intervention to be administered is a total volume of 40 mL local anesthetic containing a 1:1 mixture of 1.5% Mepivacaine: 0.5% Bupivacaine Control Dose (40 mL) Local Anesthetic Volume for Interscalene Block: Anesthetic volume: Control group: A 1:1 Mepivacaine 1.5%: Bupivacaine 0.5% mixture for a total of 40 mL Control Dose (40 mL) Local Anesthetic (Mepivacaine:Bupivacaine)
Overall Study
STARTED
77
77
Overall Study
COMPLETED
75
77
Overall Study
NOT COMPLETED
2
0

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

Effect of Local Anesthetic Dose on Interscalene Block

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Low Dose (20 mL) Local Anesthetic
n=75 Participants
Intervention to be administered is a total volume of 20 mL local anesthetic containing a 1:1 mixture of 1.5% Mepivacaine: 0.5% Bupivacaine. Low Dose (20 ml) Local Anesthetic Volume for Interscalene Block: Anesthetic volume: Investigational group: A 1:1 Mepivacaine 1.5%: Bupivacaine 0.5% mixture for a total of 20 mL Low Dose (20 mL) Local Anesthetic (Mepivacaine:Bupivacaine)
Control Dose (40 mL) Local Anesthetic
n=77 Participants
Intervention to be administered is a total volume of 40 mL local anesthetic containing a 1:1 mixture of 1.5% Mepivacaine: 0.5% Bupivacaine Control Dose (40 mL) Local Anesthetic Volume for Interscalene Block: Anesthetic volume: Control group: A 1:1 Mepivacaine 1.5%: Bupivacaine 0.5% mixture for a total of 40 mL Control Dose (40 mL) Local Anesthetic (Mepivacaine:Bupivacaine)
Total
n=152 Participants
Total of all reporting groups
Age, Continuous
51.1 years
STANDARD_DEVIATION 14.5 • n=5 Participants
50 years
STANDARD_DEVIATION 14.3 • n=7 Participants
50.6 years
STANDARD_DEVIATION 14.1 • n=5 Participants
Sex/Gender, Customized
Female
25.3 Percentage of participants
n=5 Participants
26 Percentage of participants
n=7 Participants
25.7 Percentage of participants
n=5 Participants
Sex/Gender, Customized
Male
74.7 Percentage of participants
n=5 Participants
74 Percentage of participants
n=7 Participants
74.3 Percentage of participants
n=5 Participants
Region of Enrollment
United States
75 participants
n=5 Participants
77 participants
n=7 Participants
152 participants
n=5 Participants
Body Mass Index (BMI)
27.6 kg/m^2
STANDARD_DEVIATION 4.2 • n=5 Participants
26.3 kg/m^2
STANDARD_DEVIATION 3.7 • n=7 Participants
26.8 kg/m^2
STANDARD_DEVIATION 3.9 • n=5 Participants

PRIMARY outcome

Timeframe: Difference between between baseline and postoperative.

The primary outcome will be handgrip strength as measured by a dynamometer. A reading will be obtained at baseline (before the interscalene block) and 60 minutes post-operative.

Outcome measures

Outcome measures
Measure
Low Dose (20 mL) Local Anesthetic
n=75 Participants
Intervention to be administered is a total volume of 20 mL local anesthetic containing a 1:1 mixture of 1.5% Mepivacaine: 0.5% Bupivacaine. Low Dose (20 ml) Local Anesthetic Volume for Interscalene Block: Anesthetic volume: Investigational group: A 1:1 Mepivacaine 1.5%: Bupivacaine 0.5% mixture for a total of 20 mL Low Dose (20 mL) Local Anesthetic (Mepivacaine:Bupivacaine)
Control Dose (40 mL) Local Anesthetic
n=77 Participants
Intervention to be administered is a total volume of 40 mL local anesthetic containing a 1:1 mixture of 1.5% Mepivacaine: 0.5% Bupivacaine Control Dose (40 mL) Local Anesthetic Volume for Interscalene Block: Anesthetic volume: Control group: A 1:1 Mepivacaine 1.5%: Bupivacaine 0.5% mixture for a total of 40 mL Control Dose (40 mL) Local Anesthetic (Mepivacaine:Bupivacaine)
Handgrip Strength
6.45 kg
Standard Deviation 1.6
2.98 kg
Standard Deviation 1.7

SECONDARY outcome

Timeframe: Participants will be followed every 15 minutes post-surgery until discharged from the hospital (up to 180 minutes)

Outcome measures

Outcome measures
Measure
Low Dose (20 mL) Local Anesthetic
n=75 Participants
Intervention to be administered is a total volume of 20 mL local anesthetic containing a 1:1 mixture of 1.5% Mepivacaine: 0.5% Bupivacaine. Low Dose (20 ml) Local Anesthetic Volume for Interscalene Block: Anesthetic volume: Investigational group: A 1:1 Mepivacaine 1.5%: Bupivacaine 0.5% mixture for a total of 20 mL Low Dose (20 mL) Local Anesthetic (Mepivacaine:Bupivacaine)
Control Dose (40 mL) Local Anesthetic
n=77 Participants
Intervention to be administered is a total volume of 40 mL local anesthetic containing a 1:1 mixture of 1.5% Mepivacaine: 0.5% Bupivacaine Control Dose (40 mL) Local Anesthetic Volume for Interscalene Block: Anesthetic volume: Control group: A 1:1 Mepivacaine 1.5%: Bupivacaine 0.5% mixture for a total of 40 mL Control Dose (40 mL) Local Anesthetic (Mepivacaine:Bupivacaine)
Patient Readiness to Discharge
60 minutes
Standard Deviation 5
65 minutes
Standard Deviation 7

SECONDARY outcome

Timeframe: Postoperative Day 2

Time to pain

Outcome measures

Outcome measures
Measure
Low Dose (20 mL) Local Anesthetic
n=49 Participants
Intervention to be administered is a total volume of 20 mL local anesthetic containing a 1:1 mixture of 1.5% Mepivacaine: 0.5% Bupivacaine. Low Dose (20 ml) Local Anesthetic Volume for Interscalene Block: Anesthetic volume: Investigational group: A 1:1 Mepivacaine 1.5%: Bupivacaine 0.5% mixture for a total of 20 mL Low Dose (20 mL) Local Anesthetic (Mepivacaine:Bupivacaine)
Control Dose (40 mL) Local Anesthetic
n=43 Participants
Intervention to be administered is a total volume of 40 mL local anesthetic containing a 1:1 mixture of 1.5% Mepivacaine: 0.5% Bupivacaine Control Dose (40 mL) Local Anesthetic Volume for Interscalene Block: Anesthetic volume: Control group: A 1:1 Mepivacaine 1.5%: Bupivacaine 0.5% mixture for a total of 40 mL Control Dose (40 mL) Local Anesthetic (Mepivacaine:Bupivacaine)
Duration of Analgesia
993 minutes
Interval 635.0 to 1119.0
960 minutes
Interval 759.0 to 1340.0

SECONDARY outcome

Timeframe: Postoperative Day 2

Incidence of nausea

Outcome measures

Outcome measures
Measure
Low Dose (20 mL) Local Anesthetic
n=57 Participants
Intervention to be administered is a total volume of 20 mL local anesthetic containing a 1:1 mixture of 1.5% Mepivacaine: 0.5% Bupivacaine. Low Dose (20 ml) Local Anesthetic Volume for Interscalene Block: Anesthetic volume: Investigational group: A 1:1 Mepivacaine 1.5%: Bupivacaine 0.5% mixture for a total of 20 mL Low Dose (20 mL) Local Anesthetic (Mepivacaine:Bupivacaine)
Control Dose (40 mL) Local Anesthetic
n=55 Participants
Intervention to be administered is a total volume of 40 mL local anesthetic containing a 1:1 mixture of 1.5% Mepivacaine: 0.5% Bupivacaine Control Dose (40 mL) Local Anesthetic Volume for Interscalene Block: Anesthetic volume: Control group: A 1:1 Mepivacaine 1.5%: Bupivacaine 0.5% mixture for a total of 40 mL Control Dose (40 mL) Local Anesthetic (Mepivacaine:Bupivacaine)
Side Effects
23 Participants
22 Participants

Adverse Events

Low Dose (20 mL) Local Anesthetic

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Control Dose (40 mL) Local Anesthetic

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Adverse event data not reported

Additional Information

Dr. Daniel Maalouf

HSS

Phone: (212) 606-1000

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place